Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Ouiam Bakkacha, Geoffrey L. Uy, Ibrahim Aldoss, Matthew C Foster, David A Sallman, Kendra L. Sweet, David A. Rizzieri, Peter H. Sayre, Anjali S. Advani, Ashkan Emadi, Matthew J. Wieduwilt, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Tamara Moyo, Martha L. Arellano, John E. Godwin, Bob Löwenberg, Gerwin Huls, Farhad Ravandi, Kathy Tran, John Muth, Jan Baughman, Mojca Jongen-Lavrencic, Erin Timmeny, Max S. Topp, Stefania Paolini, Kuo Guo, Teia Curtis, Jian Zhao, Jon Wigginton, Ezio Bonvini, Roland B. Walter, Jan Davidson, John F. DiPersio, Kenneth Jacobs
Institutions: MacroGenics (United States), Washington University in St. Louis, City Of Hope National Medical Center, City of Hope, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Moffitt Cancer Center, Duke University, Duke Medical Center, University of California, San Francisco, Cleveland Clinic, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of California San Diego, Moores Cancer Center, Institut Paoli-Calmettes, Vanderbilt University, Winship Cancer Institute, Providence Portland Medical Center, Erasmus MC, University Medical Center Groningen, The University of Texas MD Anderson Cancer Center, University of Würzburg, Universitätsklinikum Würzburg, University of Bologna, Fred Hutch Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2984716353